Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01625429
• Other study ID #: ABX-1201
• Status: Active, not recruiting
• Phase: Phase 2
• First received: June 19, 2012
• Last updated: November 8, 2012
• Start date: June 2012
• Est. completion date: June 2017

Study information

• Verified date: November 2012
• Source: Shanghai Cancer Hospital, China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This is a single-center, prospective, single arm phase II study to evaluate the efficacy and safety of nab-paclitaxel plus carboplatin (with trastuzumab for HER-2 positive patients) as neoadjuvant therapy in operable locally advanced breast cancer patients. The primary objective is pCR. The secondary objectives include ORR, 3-yr DFS, OS and safety. The sample size is 30.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: June 2017
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Female, between 18 and 70 years old

• Life expectancy is more than 12 months

• Breast MRI or ultrasound confirmd tumor over 3cm and biopsy comfirned invasive breast caner of stage II-III (inflammatory breast cancer excluded)

• Not accompanied with other malignancies(except for controlled carcinoma in situ of the cervix or skin basal-cell carcinoma)

• A normal bone marrow: absolute neutrophil count=1.5*10E9/L, hemoglobin=100g/L, PLT=100*10E9/L

• Normal liver and renal functions: AST=60U/L, total biliruin=1.5*upper limit of normal, serum creatinine=110umol/L, urea nitrogen=7.1mmol/L

• Normal blood coagulation function

• ECOG performance status of 0-1

• Willing to coordinate with a punch biopsy before treatment and accept neoadjuvant therapy

• Women of child-producing potential must agree to use effective contraceptive methods during the study, and a negative serum or urine pregnancy test must be obtained within 7 days prior to administration of the drugs

• Written informed consent

• For HER-2 positive patients, the HER-2 status must be determined by ICH +++ or FISH/CISH. For patients treated with trastuzumb, LVEF=55% by ultrasonic cardiogram or MUGA scan

Exclusion Criteria:

• Previous systematic or local therapy including chemotherapy for breast cancer

• Distant metastases of breast cancer are observed

• Concurrent uncontrolled lung disease, severe sepsis, active peptic ulcer requring treatment, blood coagulation disorders, serious uncontrolled diabetes, connective tissue disease or bone marrow depression, unable to tolerate neoadjuvant therapy and related treatment

• >Grade 1 peripheral neuropathy caused by any reason

• History of CHF, uncontrolled symptomatic angina, history of arrhythmias or myocardial infarction, poorly controlled hypertension (systolic pressure > 180mmHg or diastlic pressure > 100 mmHg)

• Lactational or gestational breast cancer

• Not willing to accept a punch biopsy before treatment and neoadjuvant therapy

• Psychopath or any other reasons that would preclude compliane with treatment

• Known serious allergy to any of the study drugs or excipients

• Participation in another study requiring administration of an in investigational drug or biological agent at present or recently (within the last 30 days prior to screening visit)

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• nab-paclitaxel
nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Cancer Hospital, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pathological complete response rate	The percentage of patients with a pathological complete response after neoadjuvant therapy	Obtained within six months of the last patient's enrollment	No
Secondary	Overall response rate	The percentage of patients with complete response or partial response after neoadjuvant therapy	Obtained within six months of the last patient's enrollment	No
Secondary	Three-year disease free survival	The percentage of patients who survive without breast cancer recurrence or metastases three years after surgery	Obtained within 42 months after last patient's enrollment	No
Secondary	Overall survival	The overall survival time of all patients enrolled in the study presented by survival curve and median value	Obtained around 5 years after the last patient's erollment	No
Secondary	Safety	List and frequencies of adverse events occured during and one-month after the investigational drug treatment	Obtained around six months after the last patient's enrollment	Yes